GMMA-Based Vaccines: The Known and The Unknown

Generalized Modules for Membrane Antigens (GMMA) are outer membrane vesicles derived from Gram-negative bacteria engineered to provide an over-vesiculating phenotype, which represent an attractive platform for the design of affordable vaccines. GMMA can be further genetically manipulated to modulate the risk of systemic reactogenicity and to act as delivery system for heterologous polysaccharide or protein antigens. GMMA are able to induce strong immunogenicity and protection in animal challenge models, and to be well-tolerated and immunogenic in clinical studies. The high immunogenicity could be ascribed to their particulate size, to their ability to present to the immune system multiple antigens in a natural conformation which mimics the bacterial environment, as well as to their intrinsic self-adjuvanticity. However, GMMA mechanism of action and the role in adjuvanticity are still unclear and need further investigation. In this review, we discuss progresses in the development of the GMMA vaccine platform, highlighting successful applications and identifying knowledge gaps and potential challenges.

[1]  R. Rappuoli,et al.  Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension , 2021, Frontiers in Immunology.

[2]  N. Ravenscroft,et al.  Conformational and Immunogenicity Studies of the Shigella flexneri Serogroup 6 O-Antigen: The Effect of O-Acetylation , 2021, Vaccines.

[3]  I. Ferlenghi,et al.  Stability of Outer Membrane Vesicles-Based Vaccines, Identifying the Most Appropriate Methods to Detect Changes in Vaccine Potency , 2021, Vaccines.

[4]  P. Keim,et al.  Burkholderia pseudomallei OMVs derived from infection mimicking conditions elicit similar protection to a live-attenuated vaccine , 2021, NPJ vaccines.

[5]  F. Necchi,et al.  Effect of O-Antigen Chain Length Regulation on the Immunogenicity of Shigella and Salmonella Generalized Modules for Membrane Antigens (GMMA) , 2021, International journal of molecular sciences.

[6]  Patrick S. Gellings,et al.  Bacterial-Derived Outer Membrane Vesicles are Potent Adjuvants that Drive Humoral and Cellular Immune Responses , 2021, Pharmaceutics.

[7]  F. Mancini,et al.  Dissecting the contribution of O-Antigen and proteins to the immunogenicity of Shigella sonnei generalized modules for membrane antigens (GMMA) , 2021, Scientific reports.

[8]  F. Mancini,et al.  Salmonella Paratyphi A Outer Membrane Vesicles Displaying Vi Polysaccharide as a Multivalent Vaccine against Enteric Fever , 2020, Infection and Immunity.

[9]  C. MacLennan,et al.  Outer membrane vesicle vaccines. , 2020, Seminars in immunology.

[10]  Brunella Brunelli,et al.  GMMA Is a Versatile Platform to Design Effective Multivalent Combination Vaccines , 2020, Vaccines.

[11]  F. Mancini,et al.  Outer membrane vesicles: moving within the intricate labyrinth of assays that can predict risks of reactogenicity in humans , 2020, Human vaccines & immunotherapeutics.

[12]  F. Mancini,et al.  OMV Vaccines and the Role of TLR Agonists in Immune Response , 2020, International journal of molecular sciences.

[13]  F. Berti,et al.  Improving efficacy of glycoconjugate vaccines: from chemical conjugates to next generation constructs. , 2020, Current opinion in immunology.

[14]  F. Necchi,et al.  GMMA and Glycoconjugate Approaches Compared in Mice for the Development of a Vaccine against Shigella flexneri Serotype 6 , 2020, Vaccines.

[15]  Simon Youssef,et al.  Quantitative modeling of synthetic gene transfer , 2011 .

[16]  Charles Anderson,et al.  Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230 , 2019, npj Vaccines.

[17]  J. Garcia-Vallejo,et al.  Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8+ T cells. , 2019, Acta biomaterialia.

[18]  D. Cohen,et al.  Serum IgG antibodies to Shigella lipopolysaccharide antigens – a correlate of protection against shigellosis , 2019, Human vaccines & immunotherapeutics.

[19]  E. Marchetti,et al.  Booster Vaccination With GVGH Shigella sonnei 1790GAHB GMMA Vaccine Compared to Single Vaccination in Unvaccinated Healthy European Adults: Results From a Phase 1 Clinical Trial , 2019, Front. Immunol..

[20]  S. Kent,et al.  Immunological basis for enhanced immunity of nanoparticle vaccines , 2019, Expert review of vaccines.

[21]  Nilay Shah,et al.  Emerging Technologies for Low‐Cost, Rapid Vaccine Manufacture , 2018, Biotechnology journal.

[22]  Nilay Shah,et al.  Emerging Technologies for Low-Cost, Rapid Vaccine Manufacture. , 2019, Biotechnology journal.

[23]  S. Clare,et al.  Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella , 2018, Proceedings of the National Academy of Sciences.

[24]  R. Rappuoli.  Glycoconjugate vaccines: Principles and mechanisms , 2018, Science Translational Medicine.

[25]  D. Putnam,et al.  Immunization with outer membrane vesicles displaying conserved surface polysaccharide antigen elicits broadly antimicrobial antibodies , 2018, Proceedings of the National Academy of Sciences.

[26]  I. Henderson,et al.  IgG Responses to Porins and Lipopolysaccharide within an Outer Membrane-Based Vaccine against Nontyphoidal Salmonella Develop at Discordant Rates , 2018, mBio.

[27]  P. Njuguna,et al.  A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine against Shigella sonnei Administered Intramuscularly to Adults from a Shigellosis-Endemic Country , 2017, Front. Immunol..

[28]  G. Grandi,et al.  Synergistic Protective Activity of Tumor-Specific Epitopes Engineered in Bacterial Outer Membrane Vesicles , 2017, Front. Oncol..

[29]  Yihuan Deng,et al.  Immune Response of A Novel ATR-AP205-001 Conjugate Anti-hypertensive Vaccine , 2017, Scientific Reports.

[30]  I. Henderson,et al.  Contribution of factor H-Binding protein sequence to the cross-reactivity of meningococcal native outer membrane vesicle vaccines with over-expressed fHbp variant group 1 , 2017, PloS one.

[31]  O. Finco,et al.  Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe , 2017, EBioMedicine.

[32]  D. Putnam,et al.  Designer outer membrane vesicles as immunomodulatory systems – Reprogramming bacteria for vaccine delivery , 2017, Advanced drug delivery reviews.

[33]  Michael R. King,et al.  Safe Recombinant Outer Membrane Vesicles that Display M2e Elicit Heterologous Influenza Protection. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  M. Hobbs,et al.  Experimental Vaccine Induces Th1-driven Immune Responses and Resistance to Neisseria gonorrhoeae Infection in a Murine Model , 2017, Mucosal Immunology.

[35]  F. Necchi,et al.  Characterization of O-antigen delivered by Generalized Modules for Membrane Antigens (GMMA) vaccine candidates against nontyphoidal Salmonella. , 2017, Vaccine.

[36]  M. Feldman,et al.  Glycoengineered Outer Membrane Vesicles as a Platform for Vaccine Development. , 2017, Methods in enzymology.

[37]  O. Levy,et al.  A Meningococcal Outer Membrane Vesicle Vaccine Incorporating Genetically Attenuated Endotoxin Dissociates Inflammation from Immunogenicity , 2016, Front. Immunol..

[38]  R. Bishop.  Polymorphic Regulation of Outer Membrane Lipid A Composition , 2016, mBio.

[39]  G. Tunheim,et al.  Immune responses of a meningococcal A + W outer membrane vesicle (OMV) vaccine with and without aluminium hydroxide adjuvant in two different mouse strains , 2016, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[40]  J. Kranich,et al.  How Follicular Dendritic Cells Shape the B-Cell Antigenome , 2016, Front. Immunol..

[41]  F. Necchi,et al.  Toll-Like Receptor Activation by Generalized Modules for Membrane Antigens from Lipid A Mutants of Salmonella enterica Serovars Typhimurium and Enteritidis , 2016, Clinical and Vaccine Immunology.

[42]  M. Kuehn,et al.  Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions , 2015, Nature Reviews Microbiology.

[43]  M. Stork,et al.  Outer membrane vesicles as platform vaccine technology , 2015, Biotechnology journal.

[44]  A. Colucci,et al.  Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB , 2015, PloS one.

[45]  L. Kiessling,et al.  Multivalent Antigens for Promoting B and T Cell Activation. , 2015, ACS chemical biology.

[46]  Yi Ping Li,et al.  An Impaired Inflammatory Cytokine Response to Gram-Negative LPS in Human Neonates is Associated with the Defective TLR-Mediated Signaling Pathway , 2015, Journal of Clinical Immunology.

[47]  C. Leclerc,et al.  Decoration of Outer Membrane Vesicles with Multiple Antigens by Using an Autotransporter Approach , 2014, Applied and Environmental Microbiology.

[48]  I. Ferlenghi,et al.  Modulation of Endotoxicity of Shigella Generalized Modules for Membrane Antigens (GMMA) by Genetic Lipid A Modifications , 2014, The Journal of Biological Chemistry.

[49]  D. Caugant,et al.  A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA). , 2014, Vaccine.

[50]  A. Pierleoni,et al.  Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro , 2013, Journal of extracellular vesicles.

[51]  L. Maggiore,et al.  High Yield Production Process for Shigella Outer Membrane Particles , 2012, PloS one.

[52]  Ronald J. Moore,et al.  Quantitative proteomics analysis of adsorbed plasma proteins classifies nanoparticles with different surface properties and size , 2011, Proteomics.

[53]  Brenda S. Collins,et al.  Gram-negative outer membrane vesicles in vaccine development. , 2011, Discovery medicine.

[54]  J. Moon,et al.  A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. , 2011, Vaccine.

[55]  Ping Chen,et al.  A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. , 2010, Vaccine.

[56]  B. Zomer,et al.  Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. , 2010, Vaccine.

[57]  A. Pollard,et al.  Maintaining protection against invasive bacteria with protein–polysaccharide conjugate vaccines , 2009, Nature Reviews Immunology.

[58]  Katrin Schwarz,et al.  Nanoparticles target distinct dendritic cell populations according to their size , 2008, European journal of immunology.

[59]  G. Grandi,et al.  Proteomics Characterization of Outer Membrane Vesicles from the Extraintestinal Pathogenic Escherichia coli ΔtolR IHE3034 Mutant*S , 2008, Molecular & Cellular Proteomics.

[60]  T. Phan,et al.  Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells , 2007, Nature Immunology.

[61]  C. Raetz,et al.  Lipid A modification systems in gram-negative bacteria. , 2007, Annual review of biochemistry.

[62]  C. Stead,et al.  Diversity of endotoxin and its impact on pathogenesis. , 2006 .

[63]  K. Fukase,et al.  Intrinsic conformation of lipid A is responsible for agonistic and antagonistic activity. , 2000, European journal of biochemistry.

[64]  M. Koch,et al.  Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion. , 2000, European journal of biochemistry.

[65]  A. Halstensen,et al.  Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine. , 1998, Developments in biological standardization.

[66]  T. Kirikae,et al.  Bacterial endotoxin: molecular relationships of structure to activity and function , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[67]  D. Fearon,et al.  CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. , 1992, Science.

[68]  A. Sutton,et al.  Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates , 1980, The Journal of experimental medicine.